Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow OCULAR THERAPEUTIX, INC

Get SEC filing alerts via email and in your feed for OCULAR THERAPEUTIX, INC

OCUL

OCULAR THERAPEUTIX, INC

About OCULAR THERAPEUTIX, INC

Ocular Therapeutix is a biopharmaceutical company specializing in innovative ophthalmic treatments. It develops bioresorbable hydrogel-based drug delivery systems for retinal diseases, glaucoma, and ocular inflammation. Its core products include DEXTENZA, an FDA-approved corticosteroid, and pipeline candidates like AXPAXLI for wet AMD and PAXTRAVA for glaucoma. The company's technology aims to reduce treatment burden, improve patient compliance, and address unmet needs in eye care markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from OCULAR THERAPEUTIX, INC

1
1
OCULAR THERAPEUTIX, INC Ocular Therapeutix Reports Fiscal Year 2025 Results with Focus on Retina Program

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
OCULAR THERAPEUTIX, INC Ocular Therapeutix Reports $193.5 Million Net Loss for 2024, Increases DEXTENZA Sales by 9.7%

Via official filing (AI summary) | about 1 year ago | 0 comments